Superoxide Anion (O2-•) Leading to Pulmonary Toxicity of Metal-Organic Frameworks (MOFs)

Metal-organic frameworks (MOFs) have attracted significant attention for their versatility in therapeutic and diagnostic roles, yet their potential impact on pulmonary toxicity remains largely unexplored. There is an urgent necessity to comprehensively investigate their biological impacts. Herein, w...

Description complète

Détails bibliographiques
Publié dans:Langmuir : the ACS journal of surfaces and colloids. - 1985. - 41(2025), 20 vom: 27. Mai, Seite 12510-12519
Auteur principal: Zhang, Yule (Auteur)
Autres auteurs: Zhang, Yatian, Yang, Zhijin, Xue, Zhiwei, Zhou, Lianchen, Chen, Mengya, Zhu, Mingming, Wu, Qixun, Li, Yuhao, Kang, Shifei, Zheng, Lulu, Zhang, Dawei
Format: Article en ligne
Langue:English
Publié: 2025
Accès à la collection:Langmuir : the ACS journal of surfaces and colloids
Sujets:Journal Article Metal-Organic Frameworks Superoxides 11062-77-4
Description
Résumé:Metal-organic frameworks (MOFs) have attracted significant attention for their versatility in therapeutic and diagnostic roles, yet their potential impact on pulmonary toxicity remains largely unexplored. There is an urgent necessity to comprehensively investigate their biological impacts. Herein, we examined the cytotoxicity, oxidative stress, and pulmonary injury after UIO-66, ZIF-8, and MOF-199 stimulation, with a focus on their impact on lung cells and tissue. Crucially, our mechanistic investigations definitively elucidated that the pulmonary toxicity of MOF-199 is primarily driven by the excessive generation of superoxide anion (O2-•). This superoxide-driven ROS cascade subsequently underlies the observed cellular damage, including calcium dysregulation and apoptosis, and instigates the inflammatory response leading to lung tissue injury. Conversely, UIO-66 and ZIF-8 generated the minimal superoxide level. This study provides crucial insights into the safety of MOFs and stresses the need for careful design to optimize both their functionality and biocompatibility for safe biomedical use
Description:Date Completed 27.05.2025
Date Revised 27.05.2025
published: Print-Electronic
Citation Status MEDLINE
ISSN:1520-5827
DOI:10.1021/acs.langmuir.5c00367